Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 2, 2007, Pages 278-285

  Razafindratsita, Alain ^a   Saint Lu, Nathalie ^a   Mascarell, Laurent ^a   Berjont, Nathalie ^a   Bardon, Thierry ^b   Betbeder, Didier ^c   Van Overtvelt, Laurence ^a   Moingeon, Philippe ^a  

^a Research and Development   (France)

^b CEVA SANTÉ ANIMALE   (France)

^c IMPRT   (France)

Author keywords

Allergy vaccines; mucosal formulation; sublingual immunotherapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 5; MALTODEXTRIN; OVALBUMIN;

ADOPTIVE TRANSFER; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PLETHYSMOGRAPHY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT ALLERGY; SENSITIZATION;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHITIS; CELL PROLIFERATION; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOTHERAPY; INTERLEUKIN-10; INTERLEUKIN-5; LUNG; LYMPH NODES; MICE; MICE, INBRED BALB C; MOUTH MUCOSA; OVALBUMIN; RESPIRATORY MUCOSA; SPLEEN; T-LYMPHOCYTES; TISSUE ADHESIVES; TREATMENT OUTCOME;

EID: 34548693921     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.04.009     Document Type: Article

References (34)

1. Canonica G.W., and Passalacqua G. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients. Allergy 61 suppl 81 (2006) 20-23
2. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341 (1999) 468-475
3. Wilson D.R., Lima M.T., and Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 60 (2005) 4-12
4. Akdis C.A., Barlan I.B., Bahceciler N., and Akdis M. Immunological mechanisms of sublingual immunotherapy. Allergy 61 suppl 81 (2006) 11-14
5. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., and Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 61 (2006) 151-165
6. Passalacqua G., Guerra L., Compalati E., Fumagalli F., Cirillo A., and Canonica G.W. New insights in sublingual immunotherapy. Curr Allergy Asthma Rep 6 (2006) 407-412
7. Epstein M.M. Do mouse models of allergic asthma mimic clinical disease?. Int Arch Allergy Immunol 133 (2004) 84-100
8. Liu Y.H., Kao M.C., Lai Y.L., and Tsai J.J. Efficacy of local nasal immunotherapy for Dp2-induced airway inflammation in mice: using Dp2 peptide and fungal immunomodulatory peptide. J Allergy Clin Immunol 112 (2003) 301-310
9. Naito S., Taneichi M., Kato H., Tanaka Y., Ami Y., Suzaki Y., et al. Selective inhibition of systemic anti-OVA IgE production in response to oral pre-treatment with OVA-liposome conjugates. Int Arch Allergy Immunol 129 (2002) 314-319
10. Omata N., Ohshima Y., Yasutomi M., Yamada A., Karasuyama H., and Mayumi M. Ovalbumin-specific IgE modulates ovalbumin-specific T-cell response after repetitive oral antigen administration. J Allergy Clin Immunol 115 (2005) 822-827
11. Taube C., Dakhama A., and Gelfand E.W. Insights into the pathogenesis of asthma utilizing murine models. Int Arch Allergy Immunol 135 (2004) 173-186
12. Murphy K.M., Heimberger A.B., and Loh D.Y. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250 (1990) 1720-1723
13. Baudner B.C., Balland O., Giuliani M.M., Von H.P., Rappuoli R., Betbeder D., et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun 70 (2002) 4785-4790
14. El mir S., Casanova A., Betbeder D., and Triebel F. A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration. Eur J Cancer 37 (2001) 1053-1060
15. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G.L., Irvin C.G., et al. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 156 (1997) 766-775
16. Kline J.N., Kitagaki K., Businga T.R., and Jain V.V. Treatment of established asthma in a murine model using CpG oligodeoxynucleotides. Am J Physiol Lung Cell Mol Physiol 283 (2002) L170-L179
17. Holt P.G., Vines J., and Britten D. Sublingual allergen administration, I: selective suppression of IgE production in rats by high allergen doses. Clin Allergy 18 (1988) 229-234
18. Sun J.B., Cuburu N., Blomquist M., Li B.L., Czerkinsky C., and Holmgren J. Sublingual tolerance induction with antigen conjugated to cholera toxin B subunit induces Foxp3+CD25+CD4+ regulatory T cells and suppresses delayed-type hypersensitivity reactions. Scand J Immunol 64 (2006) 251-259
19. Brimnes J., Kildsgaard J., Jacobi H., and Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 37 (2007) 488-497
20. Ippoliti F., De Santis W., Volterrani A., Lenti L., Canitano N., Lucarelli S., et al. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol 14 (2003) 216-221
21. Bahceciler N.N., Arikan C., Taylor A., Akdis M., Blaser K., Barlan I.B., et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 136 (2005) 287-294
22. Malling H.J. Sublingual immunotherapy: efficacy: methodology and outcome of clinical trials. Allergy 61 suppl 81 (2006) 24-28
23. Bagnasco M., Mariani G., Passalacqua G., Motta C., Bartolomei M., Falagiani P., et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 100 (1997) 122-129
24. Bagnasco M., Altrinetti V., Pesce G., Caputo M., Mistrello G., Falagiani P., et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 138 (2005) 197-202
25. Novak N. Targeting dendritic cells in allergen immunotherapy. Immunol Allergy Clin North Am 26 (2006) 307-319 viii
26. Jutel M., Akdis M., Blaser K., and Akdis C.A. Mechanisms of allergen specific immunotherapy: T-cell tolerance and more. Allergy 61 (2006) 796-807
27. Larche M., Akdis C.A., and Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6 (2006) 761-771
28. Francis J.N., Till S.J., and Durham S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol 111 (2003) 1255-1261
29. Mamessier E., Birnbaum J., Dupuy P., Vervloet D., and Magnan A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 36 (2006) 704-713
30. Till S.J., Francis J.N., Nouri-Aria K., and Durham S.R. Mechanisms of immunotherapy. J Allergy Clin Immunol 113 (2004) 1025-1034
31. Ciprandi G., Fenoglio D., Cirillo I., Vizzaccaro A., Ferrera A., Tosca M.A., et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 95 (2005) 38-44
32. Cosmi L., Santarlasci V., Angeli R., Liotta F., Maggi L., Frosali F., et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin Exp Allergy 36 (2006) 261-272
33. Romagnani S. Regulatory T cells: which role in the pathogenesis and treatment of allergic disorders?. Allergy 61 (2006) 3-14
34. Savolainen J., Jacobsen L., and Valovirta E. Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 61 (2006) 1184-1190